ARCADIA: AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
- Study Investigators: Dr. Claude Hemphill
- Sponsor: NIH/NINDS
- Status: Recruiting
- ClinicalTrials.gov Identifier: NCT03192215
- Phase: Phase 3
- Intervention: Active treatment will be either apixaban or aspirin for stroke prevention
- Duration of Participation: minimum 1.5 years, maximum 7 years
Purpose of the Study:
ARCADIA aims to determine which blood thinner, apixaban (Eliquis) or aspirin, is better at preventing future strokes for patients with a stroke of undetermined source.
Eligibility
You may be eligible for this study if you have had an ischemic stroke in the last 6 months that was
What to Expect
Testing: Eligible participants will be tested for a marker of atrial cardiopathy. We do this by taking a small sample of blood and reviewing tests that were completed in the hosptial for your stroke.
If you present with a marker of atrial cardiopathy, you will be eligible to receive study treatment. If you decide to proceed with randomization a computer will randomly assign you to a study group:
Group 1: Aspirin 81 milligrams once per day, plus a placebo (inactive) pill twice per day that looks identical to the apixaban pills of Group 2.
OR
Group 2: Apixaban 5 milligrams twice per day (or 2.5 milligrams twice per day in some cases), plus a placebo (inactive) pill once per day that looks identical to the aspirin pill of Group 1.
The Frequency of Visits: After screening and randomization, visits occur every three months. Participants may complete visits onsite or remotely.
Costs: There is no cost to you for participation in ARCADIA. Participants will be paid $25 for each in person visit completed throughout the duration of the study.
Contact Information
Study Coordinator: Jonathan Shih, BS Email:[email protected]